Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness

Noel Hannan, Zaf Hamzah, Henry Omoniyi Akinpeloye, David Meagher

Research output: Contribution to journalArticlepeer-review

Abstract

The combination of mirtazapine and venlafaxine has been suggested as a treatment option for difficult to treat depressive illness. We describe 32 patients with persistent depressive illness (44% male; mean age 42 years; mean 2.5 previous antidepressant trials) that received mirtazapine and venlafaxine in combination at some point over the 3 year period between 2002 and 2005. Clinical response rates (CGI-improvement score of two or less) were 44% at 4 weeks and 50% at 8 weeks. At 6 month review, 18 patients (56% of the original cohort and 75% of those still receiving treatment) had significantly responded. Clinical response typically occurred at moderate and high dose treatment with both agents. A total of 44% experienced some adverse effects with sedation (19%) and weight gain (19%) most frequent. Five patients discontinued treatment due to these effects. No serious adverse effects were linked to the combination treatment. We discuss the implications of these findings for the use of venlafaxine and mirtazapine in combination in more difficult to treat patients with depression.

Original languageEnglish
Pages (from-to)161-164
Number of pages4
JournalJournal of Psychopharmacology
Volume21
Issue number2
DOIs
Publication statusPublished - Mar 2007

Keywords

  • Combination treatment
  • Depression
  • Mirtazapine
  • Venlafaxine

Fingerprint

Dive into the research topics of 'Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness'. Together they form a unique fingerprint.

Cite this